TRAIL重组蛋白诱导肝癌细胞HepG2凋亡的研究

目的研究重组人肿瘤坏死因子相关的凋亡诱导配体（TRAIL）蛋白诱导肝癌细胞HepG2的凋亡作用和意义。方法HepG2细胞经重组人可溶性TRAIL蛋白处理后,以MTT法测定细胞存活率、流式细胞术检测细胞凋亡指数。结果TRAIL蛋白对HepG2的作用存在较好的量效和时效关系,其最佳作用剂量和最佳作用时间分别为1 000 ng/ml和24h;1 000 ng/ml的TRAIL蛋白作用24 h后,HepG2肝癌细胞的存活率降至45%,凋亡指数达51%。结论TRAIL重组蛋白能通过诱导细胞凋亡的方式杀伤一定量的HepG2肝癌细胞,有可能成为潜在的抗肝癌新药。

Apoptosis-inducing Effect of HrsTRAIL on Hepatoma Cell Line HepG2

Objective To study the apoptosis-inducing effect and its significance of human recombination soluble TRAIL （HrsTRAIL） on hepatoma cell line HepG2. Methods HepG2 cells were treated with HrsTRAIL and then the viability of HepG2 cells was measured by microcuhure tetrazolium dye （MTI＇） assay and apoptosis index was demonstrated by fluorescence-activated cell sorting （FACS）. Results HrsTRAIL had potent antitumor activity in a time- and dose-dependent manner. After co-incu- bations of the HepG2 cells in the presence of HrsTRAIL at a concentration of 1 000 ng/ml for 24 hours, the viability of HepG2 cells decreased to 45% and the apoptosis index reached to 51%. Conclusion HrsTRAIL can kill HepG2 cells by inducing apoptosis, so HrsTRAIL might be a potential new cytotoxic drug for PHC.